Navigation Links
UTMB collaborates on program targeting potential bioterrorist pathogens Ebola and Marburg
Date:3/5/2014

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center have been awarded up to $26 million to advance treatments of the highly lethal hemorrhagic fever viruses Ebola and Marburg.

These filoviruses are considered "Tier 1" pathogens by the U.S. Department of Health and Human Services, meaning they are considered agents with the highest risk of being deliberately misused by bioterrorists to cause mass casualties and produce devastating effects to the economy, critical infrastructure and public confidence.

There are no vaccines or treatments approved for human use against filoviruses, and infection causes high mortality rates that range between 50 and 90 percent.

The researchers will develop and test new vaccines and broad spectrum treatments to address this critical problem.

The award, to Dr. Thomas Geisbert, a professor in UTMB's Department of Microbiology and Immunology and a member of the Institute for Human Infections and Immunity and Galveston National Laboratory, is a collaborative Center of Excellence for Translational Research grant supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The grant funds will be distributed over five years.

Geisbert is an internationally recognized virologist, with more than 24 years of hands-on experience performing BSL-4 studies involving animals.

"We are very excited about this new grant as it combines three of the most promising post-exposure treatments that have shown the ability to completely protect animals against these deadly viruses," said Geisbert.

"We are very appreciative of the support we have received from NIAID/NIH and look forward to working with them and with our corporate partners to further develop these most promising interventions for human use."

Geisbert will collaborate with Jo
'/>"/>

Contact: Raul Reyes
rareyes@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1 2

Related biology news :

1. Life Technologies Collaborates with Canadian Centre for DNA Barcoding on Species Biodiversity Study
2. Mainz University collaborates with 3 Chinese universities in research and teaching
3. Florida Hospital collaborates with VTT of Finland
4. Feinstein Institute collaborates with GSK, UPenn, MIT to research bodys electrical impulses
5. IRSF announces 2013 awards and implements new Translational Program
6. NYBG launches Amazon Forest Program to help conserve Earths largest intact forest
7. Pilot program to let US high-school students experience Antarctic science at a Chilean station
8. Study finds Catalina Island Conservancy contraception program effectively manages bison population
9. Programming smart molecules
10. Antibiotic-resistant typhoid likely to spread despite drug control program
11. Ambitious science program will aid fishing industry and monitor effects of climate change on Europes shellfish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... University provides molecular-level insights into how cellulose the ... structural component of plant cell walls breaks down ... into any number of useful products, including liquid transportation ... Using a supercomputer that can perform functions thousands of ...
... Ridge, Ill. (December 14, 2012) It is estimated ... prevalent condition known as metabolic syndrome which is a ... factors: large waistline, high triglycerides, low HDL cholesterol, high ... a variety of risk factors that increase the likelihood ...
... 13, 2012 Swift Charities, the charitable arm of ... Fund for Diabetes Research at the Translational Genomics Research ... The Waylon Fund was Swift,s "charity of choice." ... as well as matching contributions from Phoenix-based Swift, were ...
Cached Biology News:Study fuels insight into conversion of wood to bio-oil 2Use 'em, don't lose 'em! Eating egg yolks adds nutritious benefits 2Use 'em, don't lose 'em! Eating egg yolks adds nutritious benefits 3Swift Transportation donates more than $15,000 to the Waylon Fund 2
(Date:6/2/2015)... , June 2, 2015 GOJO, inventors ... its commitment to antibiotic stewardship at the White House ... and animal health organizations and stakeholders at the White ... years to slow the emergence of antibiotic-resistant bacteria, detect ... and prevent the spread of resistant infections. ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Simple Steps Can Make a Big Difference in Managing ... As this year,s spring nasal allergy season quickly ... to manage their symptoms and ward-off allergens before they ... nasal allergy sufferers prepare for the spring nasal allergy ...
... 2 Epistem Plc,(LSE:EHP) the UK biotechnology and ... a research and development collaboration with Novartis,to identify ... of disease,areas. , The ... programme, with Novartis,s insights into disease pathways &,bioinformatics. ...
... 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... branded generic,pharmaceuticals and innovative anti-cancer pharmaceuticals in the ... to release its 2008,fourth quarter and full year ... opens in the United States. Simcere,s chief executive ...
Cached Biology Technology:Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company 2Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009 2
... Express Cloning Checker Kits provide two highly ... transformation without time-consuming plasmid preparation. By using ... all you need to do is to ... directly from the transformation plates into the ...
Recombinant Equine IL-4, CF...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
delta-like 1 homolog (Drosophila)...
Biology Products: